Sarepta Therapeutics (SRPT) could meet its revised outlook following a recent cut in its revenue guidance for Elevidys, Oppenheimer said in a Sunday report.
Sarepta cut its Elevidys sales guidance by $550 million at the midpoint in response to heightened caution from patients and caregivers following a patient death, according to the note.
Given the totality of safety and efficacy data, the report said investors are less concerned with the potential for another patient death, seeing recent case as idiosyncratic.
Elevidys being taken off the market is unlikely following supportive comments on cell and gene therapies at the FDA roundtable, the report added.
"We remain confident in management's ability to hit guidance and continue to see shares trading at unique levels we might not see again once overhangs are removed this year," the note said.
Oppenheimer reiterated its outperform rating on the stock and its price target of $123 per share.
Price: 39.95, Change: -3.06, Percent Change: -7.11
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.